HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Delaney's "negative impacts" must be shown to effect change -- House Commerce counsel.

This article was originally published in The Rose Sheet

Executive Summary

DELANEY CLAUSE REFORM BENEFITS MUST BE CLEARLY DEMONSTRATED in arguments supporting the need to change the zero-risk cancer standard for food and color additives, House Commerce Committee Counsel John Cohrssen told the Food & Drug Law Institute 1996 educational conference Dec. 10-11. "It is important to demonstrate" the benefits of Delaney clause reform so that Congress "can see why we need to make changes," he said.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel